Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01033071 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,071
- Enrollment target
NCT01033071: Completed Phase 3 study, sponsored by Takeda.
NCT01033071 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 1,071 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (39% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01033071, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,071 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the antihypertensive effect of azilsartan medoxomil plus chlorthalidone, once daily (QD), to olmesartan medoxomil plus hydrochlorothiazide in participants with moderate to severe hypertension.
Primary Outcome
The change in sitting trough clinic systolic blood pressure measured at week 12 or final visit relative to baseline. Trough blood pressure is the average of the non-missing values of the 3 serial trough sitting systolic blood pressure measurements.
Interventions
- DRUG Azilsartan medoxomil and chlorthalidone
- DRUG Olmesartan medoxomil and hydrochlorothiazide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,071 participants |
| Start Date | 2010-01 |
| Est. Completion | 2010-11 |
| Phase | Phase 3 |
What the finished NCT01033071 record still lists
NCT01033071 is an interventional study that assigns participants to a tested intervention. Its 1,071 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (39% higher).
The record links to 0 conditions, and to 2 interventions - of which Azilsartan medoxomil and chlorthalidone is the first listed.
NCT01033071 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01033071 about?
NCT01033071 is a clinical study titled "Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.". The purpose of this study is to compare the antihypertensive effect of azilsartan medoxomil plus chlorthalidone, once daily (QD), to olmesartan medoxomil plus hydrochlorothiazide in participants with moderate to severe hypertension.
What is the current status of trial NCT01033071?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,071 participants. The study started on 2010-01. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01033071?
The interventions under investigation include: Azilsartan medoxomil and chlorthalidone (DRUG), Olmesartan medoxomil and hydrochlorothiazide (DRUG).
Who is sponsoring clinical trial NCT01033071?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01033071's enrollment target sits among peer trials
1,071 272nd of 2000 higher than 1,729 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06751043 · 1,072 participants · NA
Preoperative Fasting vs. Not Fasting in Critically Ill Patients
- NCT06159673 · 1,074 participants · Phase 2
ACP-204 in Adults With Alzheimer's Disease Psychosis
- NCT06658808 · 1,075 participants · NA
Efficacy-Implementation Study for PC CARES in Rural Alaska
- NCT07084883 · 1,076 participants
Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia